Pilot study of vinblastine and bleomycin combinations in the treatment of metastatic melanoma.
Fourteen patients with advanced metastatic malignant melanoma were entered in a study with a combination of vinblastine and bleomycin (11 patients) or with this combination plus cis-dichlorodiammineplatinum(II) (three patients). Objective partial responses were seen in four of nine evaluable patients receiving vinblastine and bleomycin and in all three evaluable patients receiving vinblastine, bleomycin, and cis-dichlorodiammineplatinum(II). Although there was significant toxicity, it appeared tolerable, and no drug deaths were reported. The three drug-combination may produce less severe toxicity while maintaining a high response rate.
D001761:Bleomycin / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010865:Pilot Projects; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin